COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease.

ABSTRACT:

Introduction

With the advent of the Omicron variant, there are concerns about the efficacy of current vaccinations, especially among immunocompromised/immunosuppressed patients. Our aim was to determine the efficacy of the first booster dose against Omicron.

Methods

This was a retrospective cohort study using a well-established inflammatory bowel disease (IBD) cohort in the Veterans Health Administration. We followed patients on baseline IBD medications through the month of January 2022 during the Omicron COVID-19 wave and created adjusted models for vaccination and boosting effectiveness in reducing SARS-CoV-2 infection, hospitalization, and all-cause mortality.

Results

A total of 22,756 patients with IBD were included, of whom 34.9% had received a booster dose. Duri

SUBMITTER: Khan N 

PROVIDER: S-EPMC10045968 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature